Immix Biopharma, Inc. Common Stock
IMMXImmix Biopharma, Inc. (IMMX) is a biotechnology company focused on developing and commercializing innovative therapies in the field of immuno-oncology. The company's primary goal is to advance treatments that enhance the immune system's ability to target and eliminate cancer cells, with a particular emphasis on therapies that can improve patient outcomes in oncology.
Company News
Immix Biopharma closed an underwritten registered offering of 16.78 million shares at $8.94 per share, raising approximately $140.65 million in net proceeds. The financing was led by Morgan Stanley and BofA Securities, with participation from leading U.S. biotechnology institutional investors and mutual funds.
Immix Biopharma reported a 95% complete response rate (19 of 20 patients) in its NEXICART-2 Phase 2 trial for relapsed/refractory AL Amyloidosis using its CAR-T therapy NXC-201. All four MRD-negative patients from ASH 2025 converted to complete response, with no relapses observed to date. The company plans to initiate a Phase 3 trial in newly dia...
Immix Biopharma successfully closed a $100 million public offering of common stock and pre-funded warrants, raising approximately $93.7 million with support from leading biotechnology institutional investors and mutual funds.
Immix Biopharma priced an underwritten offering of common stock and pre-funded warrants, expecting to raise $100 million to fund NXC-201 development and corporate operations through mid-2027.
Immix Biopharma announced promising Phase 2 clinical trial results for NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis, with a 75% complete response rate and potential to increase to 95%.
